Commercial Drugmakers

Established drug franchises offer demand driven by ongoing treatment needs rather than discretionary spending or AI infrastructure budgets. With technology shares under pressure, this basket favors commercial medicines and pipeline renewal over speculative discovery businesses. Approaching earnings will test prescription demand and profitability, while patent expirations, trial setbacks and reimbursement pressure remain key risks. Launch basket (equal weight): ABBV, AMGN, MRK, LLY, JNJ, GILD Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.